🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for B-cell Acute Lymphoblastic Leukemia

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia NCT05281809Phase 21 site📍 Pittsburgh John Lister · Tests: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CD180 CART JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia NCT06689917NA1 site📍 Wuhan Tongji Hospital · Tests: JY231 Injection CAV Regimen for R/R Ph- B-ALL NCT05657652NA1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: cladribine, cytarabine,venetoclax Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies NCT06508775NA7 sites📍 Berlin📍 Cologne📍 Erlangen Miltenyi Biomedicine GmbH · Tests: MB-CART19.1, MB-CART20.1, MB-CART2019.1 Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT07572136Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: TSLPR-CART, Cyclophosphamide, Fludarabine Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL NCT06481228NA1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CAR-T cells, Venetoclax, Olverembatinib KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia NCT07246707Phase 11 site📍 Hangzhou Zhejiang University · Tests: KSV01 Injection Blinatumomab Consolidation in Real World NCT07117136n/a5 sites📍 Jacksonville📍 Chicago📍 Chicago Medical College of Wisconsin CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site📍 Prague Institute of Hematology and Blood Transfusion, Czech Republ… · Tests: Autologous CAR19 T lymphocytes Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia NCT07328503Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia NCT07400029Phase 29 sites📍 Duarte📍 Stanford📍 Basking Ridge Memorial Sloan Kettering Cancer Center · Tests: Obecabtagene Autoleucel Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia NCT07040982Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Asciminib, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients NCT05876923NA2 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Cardiopulmonary Exercise Testing, Dual X-ray Absorptiometry, Electronic Health Record Review, E… Newly-diagnosed Pediatric Ph-positive B-ALL Protocol NCT07152041Phase 324 sites📍 Hefei📍 Chongqing📍 Fuzhou Institute of Hematology & Blood Diseases Hospital, China · Tests: olverembatinib A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab NCT07422337n/a2 sites📍 Little Rock📍 Springdale Arkansas Children's Hospital Research Institute Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies NCT05887167Phase 11 site📍 Los Angeles Joshua Sasine, MD, PhD · Tests: autologous hematopoietic stem cells added to planned CAR T The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen NCT01890486n/a1 site📍 Winston-Salem Wake Forest University Health Sciences Long-term Follow up Local Registry Study of Kymriah in South Korea NCT06785818n/a18 sites📍 Bundang Gu📍 Seongnam-si📍 Gyeonggi-do Novartis Pharmaceuticals · Tests: Tisagenlecleucel Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia NCT05366218Phase 1, Phase 211 sites📍 Freiburg im Breisgau📍 Tübingen📍 Ulm University Hospital Tuebingen · Tests: Tafasitamab Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies NCT06037018Phase 11 site📍 Tianjin CytoCares Inc · Tests: CC312 Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia NCT07109219Phase 1, Phase 227 sites📍 Duarte📍 Jacksonville📍 Chicago AstraZeneca · Tests: AZD4512 monotherapy Orphan Indications for CD19 Redirected Autologous T Cells NCT04276870Phase 21 site📍 Philadelphia Stephan Grupp MD PhD · Tests: Murine CART19 Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies NCT07648264Phase 360 sites📍 Orange📍 Denver📍 Coral Springs CSL Behring · Tests: IgPro20 Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT NCT04746209Phase 21 site📍 Milwaukee Medical College of Wisconsin · Tests: Alpha/Beta T-cell and B-cell depleted HCT, Blinatumomab "Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL NCT06919393n/a3 sites📍 Meldola📍 Ravenna📍 Rimini Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: "Triple negative" adul B-cell ALL International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) NCT07476729Phase 321 sites📍 Vienna📍 Ghent📍 Prague Charite University, Berlin, Germany · Tests: Inotuzumab ozogamicin (INO), Blinatumomab The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies NCT04329728Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Los Angeles AVM Biotechnology Inc · Tests: AVM0703
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy